Rock Springs Capital Management LP Obs Eva Sa Transaction History

Rock Springs Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$1.89 - $2.55 $2.71 Million - $3.66 Million	-1,434,652 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.46 - $6.15 $27,306 - $68,265	11,100 Added 0.78%	1,434,652 $3.56 Million
Q2 2020 Aug 14, 2020	BUY	$2.01 - $5.95 $47,339 - $140,134	23,552 Added 1.68%	1,423,552 $8.39 Million
Q1 2020 May 15, 2020	BUY	$1.87 - $4.47 $1.14 Million - $2.73 Million	610,520 Added 77.33%	1,400,000 $3.37 Million
Q4 2019 Feb 14, 2020	SELL	$2.48 - $8.1 $1.41 Million - $4.62 Million	-570,520 Reduced 41.95%	789,480 $3.02 Million
Q3 2019 Nov 14, 2019	BUY	$8.22 - $11.2 $1.97 Million - $2.69 Million	240,000 Added 21.43%	1,360,000 $11.3 Million
Q2 2018 Aug 14, 2018	BUY	$10.0 - $17.87 $2.8 Million - $5 Million	280,000 Added 33.33%	1,120,000 $17 Million
Q3 2017 Nov 14, 2017	BUY	$6.38 - $8.14 $5.36 Million - $6.84 Million	840,000	840,000 $6.84 Million

88K

Ticker OBSV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,499,200
Description
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.